Literature DB >> 11386933

Tularemia as a biological weapon: medical and public health management.

D T Dennis1, T V Inglesby, D A Henderson, J G Bartlett, M S Ascher, E Eitzen, A D Fine, A M Friedlander, J Hauer, M Layton, S R Lillibridge, J E McDade, M T Osterholm, T O'Toole, G Parker, T M Perl, P K Russell, K Tonat.   

Abstract

OBJECTIVE: The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals if tularemia is used as a biological weapon against a civilian population. PARTICIPANTS: The working group included 25 representatives from academic medical centers, civilian and military governmental agencies, and other public health and emergency management institutions and agencies. EVIDENCE: MEDLINE databases were searched from January 1966 to October 2000, using the Medical Subject Headings Francisella tularensis, Pasteurella tularensis, biological weapon, biological terrorism, bioterrorism, biological warfare, and biowarfare. Review of these references led to identification of relevant materials published prior to 1966. In addition, participants identified other references and sources. CONSENSUS PROCESS: Three formal drafts of the statement that synthesized information obtained in the formal evidence-gathering process were reviewed by members of the working group. Consensus was achieved on the final draft.
CONCLUSIONS: A weapon using airborne tularemia would likely result 3 to 5 days later in an outbreak of acute, undifferentiated febrile illness with incipient pneumonia, pleuritis, and hilar lymphadenopathy. Specific epidemiological, clinical, and microbiological findings should lead to early suspicion of intentional tularemia in an alert health system; laboratory confirmation of agent could be delayed. Without treatment, the clinical course could progress to respiratory failure, shock, and death. Prompt treatment with streptomycin, gentamicin, doxycycline, or ciprofloxacin is recommended. Prophylactic use of doxycycline or ciprofloxacin may be useful in the early postexposure period.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386933     DOI: 10.1001/jama.285.21.2763

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  504 in total

Review 1.  Biological warfare and bioterrorism.

Authors:  Nicholas J Beeching; David A B Dance; Alastair R O Miller; Robert C Spencer
Journal:  BMJ       Date:  2002-02-09

2.  Effects of the putative transcriptional regulator IclR on Francisella tularensis pathogenesis.

Authors:  Brittany L Mortensen; James R Fuller; Sharon Taft-Benz; Todd M Kijek; Cheryl N Miller; Max T H Huang; Thomas H Kawula
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

4.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

5.  Human Cases of Tularemia in Armenia, 1996-2012.

Authors:  Syuzanna Melikjanyan; Karo Palayan; Artavazd Vanyan; Lilit Avetisyan; Nune Bakunts; Marine Kotanyan; Marta Guerra
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

Review 6.  Impact of CRISPR immunity on the emergence and virulence of bacterial pathogens.

Authors:  Asma Hatoum-Aslan; Luciano A Marraffini
Journal:  Curr Opin Microbiol       Date:  2013-12-29       Impact factor: 7.934

7.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

8.  T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria.

Authors:  Carmen M Collazo; Anda I Meierovics; Roberto De Pascalis; Terry H Wu; C Rick Lyons; Karen L Elkins
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

9.  An outbreak of respiratory tularemia caused by diverse clones of Francisella tularensis.

Authors:  Anders Johansson; Adrian Lärkeryd; Micael Widerström; Sara Mörtberg; Kerstin Myrtännäs; Caroline Ohrman; Dawn Birdsell; Paul Keim; David M Wagner; Mats Forsman; Pär Larsson
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

10.  Temporal transcriptional response during infection of type II alveolar epithelial cells with Francisella tularensis live vaccine strain (LVS) supports a general host suppression and bacterial uptake by macropinocytosis.

Authors:  Christopher E Bradburne; Anne B Verhoeven; Ganiraju C Manyam; Saira A Chaudhry; Eddie L Chang; Dzung C Thach; Charles L Bailey; Monique L van Hoek
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.